Maralixibat Chloride Patent Expiration

Maralixibat Chloride is Used for treating cholestatic pruritus in patients with specific liver disorders. It was first introduced by Mirum Pharmaceuticals Inc in its drug Livmarli on Sep 29, 2021.


Maralixibat Chloride Patents

Given below is the list of patents protecting Maralixibat Chloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Livmarli US11229647 Methods for treating cholestasis Feb 12, 2040 Mirum
Livmarli US11497745 Methods for treating cholestasis Feb 12, 2040 Mirum
Livmarli US11918578 Methods for treating cholestasis Feb 12, 2040 Mirum
Livmarli US10512657 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases Oct 26, 2032 Mirum
Livmarli US11229661 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases Oct 26, 2032 Mirum
Livmarli US11376251 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases Oct 26, 2032 Mirum
Livmarli US11260053 Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions May 26, 2031 Mirum



Maralixibat Chloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List